CN115671069A — 一种瑞卢戈利片剂及其制备方法
Assigned to Beijing Xinkaiyuan Pharmaceuticals Co Ltd · Expires 2023-02-03 · 3y expired
What this patent protects
本发明涉及医药技术领域,提供了一种瑞卢戈利片剂及其制备方法。该片剂包括如下重量百分比的组分:瑞卢戈利20%~40%、填充剂40%~70%、崩解剂1%~10%、粘合剂2%~8%、润滑剂0.1%~2%;其中,所述瑞卢戈利通过气流粉碎至D90小于50微米。本发明提供的瑞卢戈利片剂具有较好的体外溶出度,在体外30min溶出即可达到85%以上,溶出效果好,生物利用度高,更有利于体内吸收,且稳定性良好。
USPTO Abstract
本发明涉及医药技术领域,提供了一种瑞卢戈利片剂及其制备方法。该片剂包括如下重量百分比的组分:瑞卢戈利20%~40%、填充剂40%~70%、崩解剂1%~10%、粘合剂2%~8%、润滑剂0.1%~2%;其中,所述瑞卢戈利通过气流粉碎至D90小于50微米。本发明提供的瑞卢戈利片剂具有较好的体外溶出度,在体外30min溶出即可达到85%以上,溶出效果好,生物利用度高,更有利于体内吸收,且稳定性良好。
Drugs covered by this patent
- Orgovyx (relugolix) · MYOVANT SCIENCES
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.